Novo Nordisk A/S (NVO) Stock Price, News & Analysis

Company Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Key Stats

• Today's Range: $70.23 to $71.38
• 50-Day Range: $64.32 to $81.07
• 52-Week Range: $57.00 to $139.74
• Volume: 10.16 million shs
• Average Volume: 7.04 million shs
• Market Capitalization: $315.84 billion
• P/E Ratio: 20.93
• Dividend Yield: 2.32%
• Price Target: $112.00
• Consensus Rating: Hold

Novo Nordisk A/S Stock Analysis - MarketRank™

Novo Nordisk A/S scored higher than 87% of companies evaluated by MarketBeat, and ranked 143rd out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Novo Nordisk A/S has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 5 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Novo Nordisk A/S has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 21.35%

Earnings Growth

Earnings for Novo Nordisk A/S are expected to grow by 21.35% in the coming year, from $3.84 to $4.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novo Nordisk A/S is 20.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novo Nordisk A/S is 20.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.94.

Price to Earnings Growth Ratio

Novo Nordisk A/S has a PEG Ratio of 1.29. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novo Nordisk A/S has a P/B Ratio of 15.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.58% of the float of Novo Nordisk A/S has been sold short.

Short Interest Ratio / Days to Cover

Novo Nordisk A/S has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novo Nordisk A/S has recently decreased by 3.42%, indicating that investor sentiment is improving.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novo Nordisk A/S pays a meaningful dividend of 2.45%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novo Nordisk A/S does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novo Nordisk A/S is 48.52%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 35.19% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.58% of the float of Novo Nordisk A/S has been sold short.

Short Interest Ratio / Days to Cover

Novo Nordisk A/S has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novo Nordisk A/S has recently decreased by 3.42%, indicating that investor sentiment is improving.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.21

News Sentiment

Novo Nordisk A/S has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 47 news articles for Novo Nordisk A/S this week, compared to 46 articles on an average week.

Search Interest

108 people have searched for NVO on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.

MarketBeat Follows

44 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.

Percentage Held by Institutions

Only 11.54% of the stock of Novo Nordisk A/S is held by institutions.

NVO Stock Analysis - Frequently Asked Questions

How have NVO shares performed this year?

Novo Nordisk A/S's stock was trading at $86.02 at the start of the year. Since then, NVO shares have decreased by 17.8% and is now trading at $70.7370.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Wednesday, May, 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. The firm earned $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.52% and a trailing twelve-month return on equity of 80.94%.
Read the conference call transcript.

When did Novo Nordisk A/S's stock split?

Novo Nordisk A/S's stock split before market open on Wednesday, September 20th 2023.The 2-1 split was announced on Wednesday, September 20th 2023. The newly issued shares were issued to shareholders after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does Novo Nordisk A/S have any subsidiaries?

Novo Nordisk A/S subsidiaries include Dicerna Pharmaceuticals, Emisphere Technologies, Corvidia Therapeutics, Ziylo, Calibrium, MB2 LLC, Xellia Pharmaceuticals, and others.

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's top institutional investors include Kingstone Capital Partners Texas LLC (0.22%), DSM Capital Partners LLC (0.04%), DAVENPORT & Co LLC (0.04%) and Mirae Asset Global Investments Co. Ltd. (0.02%).
View institutional ownership trends.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novo Nordisk A/S investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), ServiceNow (NOW), Advanced Micro Devices (AMD), Salesforce (CRM) and Eli Lilly and Company (LLY).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/24/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NVO
• CIK: 353278
• Web: www.novonordisk.com
• Phone: (454) 444-8888
• Fax: 45-4449-0555
• Employees: 77,349
• Year Founded: 1923

Price Target and Rating

• Average Price Target for Novo Nordisk A/S: $112.00
• High Price Target: $160.00
• Low Price Target: $64.00
• Potential Upside/Downside: +58.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.27
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.38
• Trailing P/E Ratio: 20.91
• Forward P/E Ratio: 18.39
• P/E Growth: 1.29
• Net Income: $14.64 billion
• Net Margins: 34.52%
• Pretax Margin: 43.63%
• Return on Equity: 80.94%
• Return on Assets: 24.23%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 0.74
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $42.12 billion
• Price / Sales: 7.49
• Cash Flow: $4.13 per share
• Price / Cash Flow: 17.12
• Book Value: $4.66 per share
• Price / Book: 15.16

Miscellaneous

• Outstanding Shares: 4,465,000,000
• Free Float: 4,461,875,000
• Market Cap: $315.37 billion
• Optionable: Optionable
• Beta: 0.64